Enterome Raises $19M in Funding

| Posted on |

Here’s the summary of the funding details for Enterome:

Startup:

Founders:

  • CEO: Pierre Bélichard

Funding Details:

  • Total Raised: $19M
  • Funding Series: Not specified
  • Date of Fundraise: June 12, 2025

Investors:

  1. New Investor:
    • The Institute for Follicular Lymphoma Innovation (IFLI) – $9M
  2. Existing Specialist Investors:
    • The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) – $10M

Use of Funds:

  • To advance the Phase 1/2 trial of EO2463 OncoMimics for treating multiple forms of indolent non-Hodgkin lymphoma (iNHL).

Pipeline Candidates:

  1. EO2463 – Indolent non-Hodgkin lymphomas
  2. EO4010 – Third-line colorectal cancer
  3. EO2401 – Glioblastoma and adrenal tumors

Other Notes:

  • Each candidate has shown positive early clinical efficacy and exceptional safety and tolerability.

Source link

2025-06-12 09:21:12